Slide 1: Second Quarter 2024 Earnings Presentation
AngioDynamics Second Quarter 2024 Earnings Presentation January 5, 2024
Slide 2: Forward-Looking Statement
AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future fi
Slide 3: Corporate Developments – Q2 and YTD FY24
IDE Clinical Studies and Pathway Expansion Corporate Developments – Q2 and YTD FY24 AngioDynamics Second Quarter 2024 Earnings 3 Initiated restructuring of manufacturing footprint to a fully outsourced model Continued portfolio optimization initiatives Full-year adjusted EPS profitability expected i
Slide 4: Q2 FY24 Results (unaudited)
Q2 FY24 Results (unaudited) AngioDynamics Second Quarter 2024 Earnings 4 $ in thousands (except per share data) Q2 FY24 As Reported Q2 FY23 As Reported Change Q2 FY24 Pro Forma* Q2 FY23 Pro Forma* Change Revenue $79,073 $85,429 (7.4%) $79,073 $76,987 2.7% Med Tech Med Device $25,363 $53,710 $24,502
Slide 5: YTD FY24 Results (unaudited)
YTD FY24 Results (unaudited) AngioDynamics Second Quarter 2024 Earnings 5 $ in thousands (except per share data) YTD FY24 As Reported YTD FY23 As Reported Change YTD FY24 Pro Forma* YTD FY23 Pro Forma* Change Revenue $157,752 $166,966 (5.5%) $157,081 $150,778 4.2% Med Tech Med Device $51,224 $106,52
Slide 6: Q2 and YTD FY24 Results (pro forma)
Q2 and YTD FY24 Results (pro forma*) 6 Med Device Med Tech 3.5% growth 2.3% growth Q2 Revenue Growth Q2 FY23 Q2 FY24 Q2 Revenue Contribution Q2 FY23 Q2 FY24 Med Tech Gross Margin 62.4% Med Device Gross Margin 45.5% AngioDynamics Second Quarter 2024 Earnings Med Device Med Tech 8.3% growth 2.3% growt
Slide 7: Sales Comparison to Prior-Year Period
Sales Comparison to Prior-Year Period AngioDynamics Second Quarter 2024 Earnings 7 Med Tech Q2 FY24 YTD FY24 Auryon 12.9% 18.9% Thrombus Management* AngioVac AlphaVac (6.8%) (10.8%) 17.9% (6.7%) (9.2%) 9.5% NanoKnife® Disposables (3.6%) 12.9% NanoKnife® Capital 22.8% 29.9% Med Device Q2 FY24 YTD FY2
Slide 8: FY24 Revised Guidance
FY24 Revised Guidance 8 * FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of $0.43. AngioDynamics Second Quarter 2024 Earnings Guidance* Revised Guidance* Revenue $328 - $333 million $320 - $325 million Gross Ma
Slide 9: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 10: Reconciliation of GAAP to Non-GAAP Pro Forma Results
10 (in thousands, except per share data) (in thousands, except per share data) Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Slide 11: Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS Reconciliation of Net Income (Loss) to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items
Slide 12: Reconciliation of Non-GAAP Pro Forma Net Income (Loss)
Reconciliation of Non-GAAP Pro Forma Net Income (Loss) to Adjusted Pro Forma Net Loss and EPS Reconciliation of Non-GAAP Pro Forma Net Income (Loss) to Adjusted Pro Forma EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairment
Slide 13: Reconciliation of Pro Forma Sales and Gross Margin by Product Category
13 (in thousands) Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands)
Slide 14: Thank You
Thank You AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate, or a subsidiary. All other trademarks are property of their respective owners. © 2023 AngioDynamics, Inc.